Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    Asia Pacific Clinical Trials Market Forecast 2027 By Phases (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Therapeutic Area (Autoimmune Disease, Oncology, Cardiology, Infectious Disease, Dermatology, Ophthalmology), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: November 2021   |   Report ID: GR2004   |   Delivery: PDF  Request Free Sample

    Asia Pacific Clinical Trials Market size crossed USD 7.1 billion in 2020 and is predicted to observe around 8.1% growth rate from 2021 to 2027.

    The increasing potential in the regional market is due to the challenges faced while conducting clinical trials in developed countries of North America and Europe such as increased costs and reduced patient count. Also, the rapidly developing healthcare infrastructure in countries in Asia, particularly Southeast Asia, contributes to the regional market growth.

    Asia Pacific Clinical Trials Market

    Get more details on this report - Request Free Sample PDF

    The upgradation of healthcare IT capabilities coupled with the large-scale adoption of digital solutions to capture as well as store healthcare records is noted to act as a catalyst in the region’s prominence. Moreover, the supportive regulatory framework eases the entry point of clinical trials in the region. As the demand for novel drugs and advanced medical devices emerges, a subsequent demand for efficient, fast-paced, and reliable clinical trials program is also noted to rise.

    Asia Pacific Market, By Phases

    Phase III segment revenue was more than USD 3.6 billion in 2020. The focus of phase III clinical trials is to demonstrate and confirm the preliminary evidence gathered in the previous trials that drug is safe, beneficial and offers effective treatment for the intended indication.

    Additionally, phase III clinical trials determine if the new drug or combination of drugs is better or equivalent to the standard of care. Furthermore, significant revenue generation from phase III clinical trials is noted owing to relatively higher costs associated with it and a large patient pool involved in the study.

    Asia Pacific Market, By Study Design

    Interventional study segment will show significant growth in the Asia Pacific clinical trials market to surpass USD 9.5 billion valuation by 2027. Interventional study is noted to be amongst the top hierarchical pyramid of evidence, as it offers a better way to measure the efficacy of novel interventions. The interventional study design is widely preferred over other study designs owing to several factors such as elimination of recall bias as well as enhanced efficiency of new interventions.

    Asia Pacific Market, By Therapeutic Area

    Oncology segment accounted for USD 2.6 billion revenue in 2020. The increasing prevalence of cancer is one of the prominent factors leading to the increased investments in the clinical trials surrounding oncology. For instance, high prevalence of liver cancer is South Korea demands increasing clinical trials in the country surrounding studies involving cancer treatments.

    Asia Pacific Market, By Country

    China clinical trials market size is set to observe around 10% gains during the forecast timeframe. Emergence of severe diseases, huge patient population, increasing clinical trials and R&D are some of the country level market growth driving factors. Also, the local government is funding for drug discovery and related research studies.

    Rising number of COVID-19 cases are attracting firms to conduct trials to take advantage of the large patient pool and fast-track procedures, thereby fostering the market demand. Furthermore, increasing number of biotechnology firms are looking for APAC region including Singapore, India, China, South Korea, and Japan has propelled the regional market expansion.

    Competitive Industry Landscape

    Prominent companies in the market are Laboratory Corporation of America Holdings, IQVIA, Pharmaceutical Product Development, and PRA Health Science.

    Industry players undertake various strategies such as mergers, collaborations, acquisitions, and geographic expansions to strengthen their market share. For instance, In February 2020, PAREXEL International announced that it has completed the acquisition of Model Answers, a consultancy firm. The company has significant experience developing preclinical PK and PD models for effectiveness and neutropenia, scaling to first-in-human studies, then supporting Phase I through to NDA submission.

    Frequently Asked Question(FAQ) :

    How big is the Asia Pacific clinical trials market?
    The industry size for clinical trials in Asia Pacific was exceeded USD 7.1 billion in 2020 and will grow at a rate of 8.1% between 2021 and 2027 with rapidly developing healthcare infrastructure in Southeast Asia.
    What factors will drive the clinical trials in Asia Pacific market growth from phase III application?
    The market revenue from phase III application surpassed USD 3.6 billion in 2020 and is set to escalate owing to the involvement of a large patient pool and relatively higher costs of conducting the study.
    How will the Asia Pacific clinical trials segment value grow from oncology?
    The market share from oncology was around USD 2.6 billion in 2020 and will expand with the surging prevalence of cancer in the region.
    Why will the clinical trials industry record substantial growth in China?
    The industry share for clinical trials in China is anticipated to register 10% gains through 2027 driven by the huge patient population, emergence of severe diseases, and rising clinical trials in the country.
    Which are leading players in the Asia Pacific clinical trials landscape?
    Major clinical trial companies in the APAC are PRA Health Science, Pharmaceutical Product Development, IQVIA, Laboratory Corporation of America Holdings, and others.

    Get this research report on Asia Pacific Clinical Trials Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team


     [email protected]